摘要
2017年3月22日中国食品药品监督管理局(CFDA)批准表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)奥希替尼(Osimertinib)用于治疗EGFR T790M基因突变阳性的局部晚期或转移性非小细胞肺癌(NSCLC)。奥希替尼是第三代EGFR-TKI,治疗效果显著,副作用更小,尤其适用于对第一、二代EGFR-TKI耐药或者脑转移的病人。与含铂类治疗药物的二联化学疗法相比,奥希替尼可使NSCLC病人中位无进展生存期(PFS)延长5.7个月,疾病进展风险下降70%。该文就奥希替尼的作用机制、研究历程、药效学、药动学、不良反应,耐药机制进行综述,为临床使用提供参考。
On March 22,2017,CFDA approved Osimertinib which is a epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)to treat EGFR T790M gene mutation positive of locally advanced or metastatic non-small-cell lung cancer(NSCLC).Osimertinib is a third-generation EGFR-TKI with highly effective treatment and few side effects,especially suitable for the first and the second generation of EGFR-TKI resistance or patients with brain metastases.Compared with platinum-based duplex chemical therapy,the median duration of progression-free survival(PFS)of Osimertinib extend for 5.7 months and its disease progression risk reduce to 70%.In this paper,we review the Osimertinib of its mechanism of action,research history,pharmacodynamics,pharmacokinetics,side effects,resistance mechanisms in order to provide reference for clinical application.
作者
饶晓明
李海燕
李凯
RAO Xiaoming;LI Haiyan;LI Kai(Department of Pharmacy,Maternal and Child Health Hospital of Jiangxia District of Wuhan,Wuhan,Hubei 430200,China;The Center for Disease Control of Jiangxia District of Wuhan,Wuhan,Hubei 430200,China;Department of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430022,China)
出处
《安徽医药》
CAS
2019年第3期611-614,共4页
Anhui Medical and Pharmaceutical Journal
